HCPCS Level II · Drugs administered other than oral method
J1652Injection, fondaparinux sodium, 0.5 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1652
J1652 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, fondaparinux sodium, 0.5 mg.
It was added to HCPCS effective 01/01/2003.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Fondaparinux sodium
- Date added
- 01/01/2003
- Action effective
- 01/01/2003
- BETOS
- O1E
Related J16xx codes
- J1600Injection, gold sodium thiomalate, up to 50 mg
- J1602Injection, golimumab, 1 mg, for intravenous use
- J1610Injection, glucagon hydrochloride, per 1 mg
- J1611Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg
- J1612Injection, glucagon (gvoke), 0.01 mg
- J1626Injection, granisetron hydrochloride, 100 mcg
- J1627Injection, granisetron, extended-release, 0.1 mg
- J1628Injection, guselkumab, 1 mg
- J1630Injection, haloperidol, up to 5 mg
- J1631Injection, haloperidol decanoate, per 50 mg
- J1632Injection, brexanolone, 1 mg
- J1640Injection, hemin, 1 mg
Common questions about J1652
Is HCPCS J1652 still valid?
- Yes. J1652 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J1652?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.